# A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

> **NCT04577781** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 28 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GLPG3970
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04577781
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-12
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-04-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04577781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04577781, "A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04577781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*